Skip to main content
SpringerLink
Log in

Potential Therapeutics for Vitamin C and Cancer

  • Chapter
  • First Online:
New Insights on Vitamin C and Cancer

Part of the book series: SpringerBriefs in Cancer Research ((BRIEFSCANCER))

  • 889 Accesses

Abstract

High-dose vitamin C has proven to be cytotoxic to a wide variety of cancer cell lines (Fain et al. in BMJ 316:1661–1662, 1998; Mayland et al. in Palliat Med 19(1):17–20, 2005; Agus et al. in Cancer Res 59:4555–4558, 1999; Prasad et al. in J Am Coll Nutr 18:13–25, 1999; Hart in Alt Complement Ther 18:91–97, 2012), as well as to boost the cytotoxicity of several common chemotherapy drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chen P, Stone J, Sullivan G, et al. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med. 2011;51:681–7.

    Article  PubMed  CAS  Google Scholar 

  2. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102:13604–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009;47:32–40.

    Article  PubMed  CAS  Google Scholar 

  4. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008;105:11105–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Frömberg A, Gutsch D, Schulze D, et al. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2011;67(5):1157–66.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50(11):1610–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Ong PS, Chan SY, Ho PC. Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol. 2011;38(6):1731–9.

    PubMed  CAS  Google Scholar 

  8. Martinotti S, Ranzato E, Burlando B. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro. 2011;25(8):1568–74.

    Article  PubMed  CAS  Google Scholar 

  9. Herst PM, Broadley KW, Harper JL, et al. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med. 2012;52(8):1486–93.

    Article  PubMed  CAS  Google Scholar 

  10. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24(4):269–76.

    PubMed  Google Scholar 

  11. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969–74.

    Article  PubMed  CAS  Google Scholar 

  12. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007;22(1):7–11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139–46.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. http://clinicaltrials.gov/ct2/show/NCT01833351?term=pharmacokinetics+and+vitamin+c+and+drisko&rank=1. Accessed 17 Dec 2013.

  16. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9:285–315.

    Article  PubMed  CAS  Google Scholar 

  17. Riordan H, Jackson J, Schultz M. Case Study: High Dose intravenous Vitamin C in the Treatment of a Patient with Adrenocarcinoma of the Kidney. J Orthomol Med. 1990;5:5–7.

    Google Scholar 

  18. Jackson JA, Riordan HD, Hunninghake RE, Riordan N. High Dose intravenous Vitamin C and Long Time Survival of A Patient with Cancer of Head of the Pancreas. J Orthomol Med. 1995;10:87–8.

    Google Scholar 

  19. Riordan N, Jackson J, Riordan HD. Intravenous Vitamin C in A Terminal Cancer Patient. J Orthomol Med. 1996;11:80–2.

    Google Scholar 

  20. Riordan HD, Jackson JA, Riordan NH, Schultz M. High-dose intravenous Vitamin C in the Treatment of a Patient with Renal Cell Carcinoma of the Kidney. J Orthomol Med. 1998;13:72–3.

    Google Scholar 

  21. Riordan NH, Riordan HD, Casciari JJ. Clinical and Experimental Experiences with Intravenous Vitamin C. J Orthomolec Med. 2000;15(4):201–13.

    Google Scholar 

  22. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22(2):118–23.

    Article  PubMed  Google Scholar 

  23. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006;174(7):937–42.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976;73(10):3685–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75(9):4538–42.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Cameron E, Campbell A. Innovation vs. quality control: an ‘unpublishable’ clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses. 1991;36(3):185–9.

    Article  PubMed  CAS  Google Scholar 

  27. Creagan ET, Moertel CG, O’Fallon JR, Schutt AJ, O’Connell MJ, Rubin J, Frytak S. N Engl J Med (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer; A controlled trial. N Eng J Med. 1979;301(13):687–90.

    Article  CAS  Google Scholar 

  28. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy; A randomized double-blind comparison. N Engl J Med. 1985;312(3):137–41.

    Article  PubMed  CAS  Google Scholar 

  29. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 Nov-Dec;25(6):983–90.

    Google Scholar 

  30. Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1651–9.

    PubMed  CAS  Google Scholar 

  31. Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1030–4.

    Article  PubMed  CAS  Google Scholar 

  32. Fuchs-Tarlovsky V, Bejarano-Rosales M, Gutiérrez-Salmeán G, Casillas MA, López-Alvarenga JC, Ceballos-Reyes GM. Effect of antioxidant supplementation over oxidative stress and quality of life in cervical cancer. Nutr Hosp. 2011 Jul-Aug;26(4):819–26.

    Google Scholar 

  33. Murata A. Morishige F. Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. International Journal for Vitamin and Nutrition Research. 1982;23:101–113.

    Google Scholar 

  34. Mikirova N, Casciari J, Riordan N, Hunninghake R. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med. 2013;11(1):191.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Cameron E, Campbell A, Jack T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact. 1975;11(5):387–93.

    Article  PubMed  CAS  Google Scholar 

  36. Campbell A. Development of a papillary thyroid carcinoma in a patient while on high dosage ascorbic acid therapy. Chem Biol Interact. 1980;30(3):305–8.

    Article  PubMed  CAS  Google Scholar 

  37. Campbell A, Jack T, Cameron E. Reticulum cell sarcoma: two complete ‘spontaneous’ regressions, in response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology. 1991;48(6):495–7.

    Article  PubMed  CAS  Google Scholar 

  38. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006;174(7):937–42.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5:e11414.

    Article  PubMed  PubMed Central  Google Scholar 

  40. http://www.clinicaltrials.gov/ct2/results?term=vitamin+c+and+cancer&Search=Search. Accessed on 27 Dec 2013.

  41. Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ. 1998;316:1661–2.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  42. Mayland CR, Bennett MI. Allan K Vitamin C deficiency in cancer patients. Palliat Med. 2005;19(1):17–20.

    Article  PubMed  Google Scholar 

  43. Agus DB, Vera JC, Golde DW. Stand allocation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999;59:4555–8.

    PubMed  CAS  Google Scholar 

  44. Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr. 1999;18:13–25.

    Article  PubMed  CAS  Google Scholar 

  45. Hart J. Data support Antioxidant Use during Chemotherapy. Alt Complement Ther. 2012;18:91–7.

    Article  Google Scholar 

  46. Prasad KN, Cole WC, Kumar B, Prasad KC. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 2002;28:79–91.

    Article  PubMed  CAS  Google Scholar 

  47. Nagy B, Mucsi I, Molnar J, Varga A, Thurzo L. Chemosensitizing Effect if Vitamin C in Combination with 5-FU. In Vitro. 2003;17:289–92.

    Article  CAS  Google Scholar 

  48. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22:118–23.

    Article  PubMed  Google Scholar 

  49. Lamson DW, Brignall MS. Antioxidants in cancer therapy: their actions and interactions with oncologic therapies. Alt Med Rev. 1999;4:304–29.

    CAS  Google Scholar 

  50. Lamson DW, Brignall MS. Antioxidants in cancer therapy II: quick reference guide. Alt Med Rev. 2000;5:152–63.

    CAS  Google Scholar 

  51. Lamson DW, Brignall MS. Antioxidants in cancer III. Alt Med Rev. 2000;5:196–208.

    CAS  Google Scholar 

  52. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008;123:1227–39.

    Article  PubMed  CAS  Google Scholar 

  53. Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr. 1999;18:13–25.

    Article  PubMed  CAS  Google Scholar 

  54. Moss RW. Antioxidants against cancer. New York: Equinox Press; 2000.

    Google Scholar 

  55. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes ES, Beger HM, Clenton FJ, Osanto S. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998;9:1331–7.

    Article  PubMed  CAS  Google Scholar 

  56. Clemens MR, Muller-Ladner CI, Gey KF. Vitamins during High Dose Chemo and radio therapy. Z Ermahrungwiss. 1992;31:110–20.

    Article  CAS  Google Scholar 

  57. Schreurs WH, Odink J, Egger RJ, Wedel M, Brunning PF. The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients. In J Vitam Nutr Res. 1985;55:425–32.

    CAS  Google Scholar 

  58. Prasad KN, Kumar R. Effect of Individual and multiple antioxidant vitamins on growth and morphology of human non-tumorigenic and tumorigenic parotid acinar cell in cultures. Nutr Cancer. 1996;26:11–9.

    Article  PubMed  CAS  Google Scholar 

  59. Murata A, Murata A, Morishige F, Yamaguchi H. Polongation of survival times of terminal cancer patients by administration of large doses of Ascorbate. Int J Vitam Nutr Suppl. 1982;23:103–13.

    CAS  Google Scholar 

  60. Begley S (2008-09-16). Rethinking the war on cancer. Newsweek. Retrieved 2008-09-08.

    Google Scholar 

  61. Kolata G (April 23, 2009). Advances elusive in the drive to cure cancer. The New York Times. Retrieved 2009-05-05.

    Google Scholar 

  62. Prasad KN, Sinha PK, Ramanujam M, Sakamoto A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA. 1979;76:829–32.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. Chiang CD, Song EJ, Yang VC, Chao CCK. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung cancer cells. Biochem J. 1994;301:759–64.

    PubMed  CAS  PubMed Central  Google Scholar 

  64. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996;103:183–9.

    Article  PubMed  CAS  Google Scholar 

  65. Reddy VG, Khanna N, Singh N. Vitamin C Augments Chemotherapeutic Response of Cervical Carcinoma HeLa Cells by Stabilizing P53 Biochem. Biophys Res Commun. 2001;282:409–15.

    Article  CAS  Google Scholar 

  66. Abdel-Latif MM, Raouf AA, Sabra K, Kelleher D, Reynolds JV. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother. 2005;17(5):539–49.

    Article  PubMed  CAS  Google Scholar 

  67. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009;47(1):32–40.

    Article  PubMed  CAS  Google Scholar 

  68. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50(11):1610–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  69. Helgestad J, Pettersen R, Storm-Mathisen I, Schjerven L, Ulrich K, Smeland EB, Egeland T, Sørskaard D, Brøgger A, Hovig T, Degrt M, Lie SO. Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid. Eur J Haematol. 1990 Jan;44(1):9–17.

    Google Scholar 

  70. Martinotti S, Ranzato E, Burlando B. Toxicol In Vitro. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. 2011;25(8):1568–74.

    CAS  Google Scholar 

  71. Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, Khuri FR, Wang B, Sun SY. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res. 2006;12(1):273–80.

    Article  PubMed  CAS  Google Scholar 

  72. Frömberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2011;67(5):1157–66.

    Article  PubMed  PubMed Central  Google Scholar 

  73. An SH, Kang JH, Kim DH. MS. Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. BMB Rep. 2011;44(3):211–6.

    Article  PubMed  CAS  Google Scholar 

  74. Herst PM, Broadley KW, Harper JL, McConnell MJ. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med. 2012;52(8):1486–93.

    Article  PubMed  CAS  Google Scholar 

  75. Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, Mutti L, Biffo S, Burlando B. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. PLoS One. 2013;8(3):e58051.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  76. Okunieff P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. Am J Clin Nutr. 1991;54:1281S–3S.

    PubMed  CAS  Google Scholar 

  77. Sarna S, Bhola RK. Chemo-immunotherapeutical studies on Dalton’s lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Arch Immunol Ther Exp (Warsz). 1993;41(5–6):327–33.

    CAS  Google Scholar 

  78. Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, Anderson KC. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009;23(9):1679–86.

    Article  PubMed  CAS  Google Scholar 

  79. Prasad SB, Rosangkima G, Nicol BM. Eur J Pharmacol. Cyclophosphamide and ascorbic acid-mediated ultrastructural and biochemical changes in Dalton’s lymphoma cells in vivo. 2010;645(1–3):47–54.

    CAS  Google Scholar 

  80. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50(11):1610–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  81. Park JH, Davis KR, Lee G, Jung M, Jung Y, Park J, Yi SY, Lee MA, Lee S, Yeom CH, Kim J. Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice. Nutr Res. 2012;32(11):873–83.

    Article  PubMed  CAS  Google Scholar 

  82. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol. 1980;15(1):85–90.

    Article  PubMed  CAS  Google Scholar 

  83. Kilçiksiz S, Gökçe T, Somali I, Duransoy A, Aydin A, Yiğit S. Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature. J BU ON. 2006;11(3):355–338.

    Google Scholar 

  84. Koizumi M, Nishimura T, Kagiya T. Clinical trial of adverse effect inhibition with glucosides of vitamin C and vitamin E in radiotherapy and chemotherapy. J Can Res Ther. 2005;1:239.

    Article  CAS  Google Scholar 

  85. Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, González MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J. 2004;23(2):115–8.

    PubMed  Google Scholar 

  86. Riordan H, Jackson J, Schultz M. Case Study: High Dose intravenous Vitamin C in the Treatment of a Patient with Adrenocarcinoma of the Kidney. J Orthomol Med. 1990;5:5–7.

    Google Scholar 

  87. Jackson JA, Riordan HD, Hunninghake RE, Riordan N. High dose intravenous vitamin C and long time survival of a patient with cancer of head of the pancreas. J Orthomol Med. 1995;10:87–8.

    Google Scholar 

  88. Riordan N, Jackson J, Riordan HD. Intravenous Vitamin C in A Terminal Cancer Patient. J Orthomol Med. 1996;11:80–2.

    Google Scholar 

  89. Riordan HD, Jackson JA, Riordan NH, Schultz M. High-dose intravenous Vitamin C in the Treatment of a Patient with Renal Cell Carcinoma of the Kidney. J Orthomol Med. 1998;13:72–3.

    Google Scholar 

  90. Riordan NH, Riordan HD, Casciari JJ. Clinical and Experimental Experiences with Intravenous Vitamin C. J Orthomolec Med. 2000;15(4):201–13.

    Google Scholar 

  91. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22(2):118–23.

    Article  PubMed  Google Scholar 

  92. Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1651–9.

    PubMed  CAS  Google Scholar 

  93. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R,Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135(2):174–183.

    Google Scholar 

  94. Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1030–4.

    Article  PubMed  CAS  Google Scholar 

  95. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007 15;13(6):1762–1768.

    Google Scholar 

  96. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, Swift RA. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol. 2009;82(6):433–9.

    Article  PubMed  CAS  Google Scholar 

  97. Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9):796–800.

    Article  PubMed  CAS  Google Scholar 

  98. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983–90.

    PubMed  CAS  Google Scholar 

  99. Fuchs-Tarlovsky V, Bejarano-Rosales M, Gutiérrez-Salmeán G, Casillas MA, López-Alvarenga JC, Ceballos-Reyes GM. Effect of antioxidant supplementation over oxidative stress and quality of life in cervical cancer. Nutr Hosp. 2011;26(4):819–26.

    PubMed  CAS  Google Scholar 

  100. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012;118(9):2507–15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  101. Takahashi H, Mizuno H, Atsuo Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Med Univ. 2012;1:49–53.

    Google Scholar 

  102. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  103. Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Horwitz ME, Chao NJ, Gasparetto C. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest. 2013;31(3):172–6.

    Article  PubMed  CAS  Google Scholar 

  104. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765–75.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Development, Nutrition Program School of Public Health, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico

    Michael J. Gonzalez

  2. Department Pharmacy Practice, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico

    Jorge R. Miranda-Massari

Authors
  1. Michael J. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge R. Miranda-Massari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Gonzalez .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 The Author(s)

About this chapter

Cite this chapter

Gonzalez, M.J., Miranda-Massari, J.R. (2014). Potential Therapeutics for Vitamin C and Cancer. In: New Insights on Vitamin C and Cancer. SpringerBriefs in Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1890-4_3

Download citation

Publish with us

Policies and ethics

Search

Navigation